CN Patent

CN103998041B — 药物组合物

Assigned to Nova Laboratories Sdn Bhd · Expires 2016-08-17 · 10y expired

What this patent protects

本发明涉及包含N‑{3‑[3‑环丙基‑5‑(2‑氟‑4‑碘‑苯基氨基)‑6,8‑二甲基‑2,4,7‑三氧代‑3,4,6,7‑四氢‑2H‑吡啶并[4,3‑d]嘧啶‑1‑基]苯基}乙酰胺二甲基亚砜溶剂合物的药物组合物、在治疗中使用该组合物的方法以及制备该组合物的方法。

USPTO Abstract

本发明涉及包含N‑{3‑[3‑环丙基‑5‑(2‑氟‑4‑碘‑苯基氨基)‑6,8‑二甲基‑2,4,7‑三氧代‑3,4,6,7‑四氢‑2H‑吡啶并[4,3‑d]嘧啶‑1‑基]苯基}乙酰胺二甲基亚砜溶剂合物的药物组合物、在治疗中使用该组合物的方法以及制备该组合物的方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN103998041B
Jurisdiction
CN
Classification
—
Expires
2016-08-17
Drug substance claim
No
Drug product claim
No
Assignee
Nova Laboratories Sdn Bhd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.